| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/27/2005 | WO2003087374A9 Derivatives of the il-2 receptor gamma chain, their production and use. |
| 01/27/2005 | WO2003076565A3 Methods of using 46828, a human acyl-coa synthetase |
| 01/27/2005 | US20050022256 Triple transgenic mouse model of alzheimer's disease |
| 01/27/2005 | US20050020830 Heteroaryl fused azapolycyclic compounds |
| 01/27/2005 | US20050020813 Streptococcus pneumoniae proteins and nucleic acids |
| 01/27/2005 | US20050020691 Pharmaceutical preparations comprising substituted beta-aminoalcohols |
| 01/27/2005 | US20050020677 Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use |
| 01/27/2005 | US20050020670 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofuran |
| 01/27/2005 | US20050020665 For example, N-hydroxy-N-(1-benzo[b]thien-2-ylethyl) acetamide,1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxy urea,N-hydroxy-N-(1-benzo[b]thien-2-ylethyl)-N'-methyl urea |
| 01/27/2005 | US20050020660 For example, 3-(3-methoxy-1-azabicyclo[2.2.2]oct-3-yl)-1,1-diphenyl-2-propyn-1-ol, 3-[(3R)-3-methoxy-1-azabicyclo [2.2.2]oct-3-yl]-1,1-diphenyl-2-propyn-1-ol; particularly suited for treating urinary incontinence |
| 01/27/2005 | US20050020657 Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2 |
| 01/27/2005 | US20050020634 Acat inhibitors; cardiovascular disorders; restenosis; Alzheimer's disease |
| 01/27/2005 | US20050020632 Optical isomers of an iloperidone metabolite |
| 01/27/2005 | US20050020629 Pain management |
| 01/27/2005 | US20050020627 Compositions for improving mental concentration |
| 01/27/2005 | US20050020621 Prevent reduced blood flow to brain |
| 01/27/2005 | US20050020618 Antidiabetic agents; obesity |
| 01/27/2005 | US20050020616 Central nervous system and psychological disorders |
| 01/27/2005 | US20050020610 Mixture of disaccharides, polysaccharides and solvent |
| 01/27/2005 | US20050020609 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 01/27/2005 | US20050020604 5-HT receptor ligands and uses thereof |
| 01/27/2005 | US20050020602 Bone disorders; reduction concentration of parathyroid hormone in blood |
| 01/27/2005 | US20050020601 Novel pyrazinones as CRF1 receptor antagonists |
| 01/27/2005 | US20050020599 4-(1,3,4,-thiadiazol-2-yl)-1,4-diazabicyclo-[3.2.2]nonane derivatives, preparation and therapeutic use thereof |
| 01/27/2005 | US20050020598 Antiserotonine agents; central nervous system disorders; anxiolytic agents; cognition activators; schizophrenia ; antidepressants; Alzheimer's disease; Parkinson's disease |
| 01/27/2005 | US20050020597 Attention deficit disorders; hyperactivity; post-trauma stress disorders; anxiolytic agents; obsessive compulsive disorders; analgesics; Parkinson's disease |
| 01/27/2005 | US20050020585 Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| 01/27/2005 | US20050020584 Benzamide derivatives as antagonists of orexin receptors |
| 01/27/2005 | US20050020583 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 01/27/2005 | US20050020575 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands |
| 01/27/2005 | US20050020573 5HT2c receptor modulators |
| 01/27/2005 | US20050020571 Antiserotonine agents; psycholgical disorders; headaches |
| 01/27/2005 | US20050020568 Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1] octane, the preparation thereof and the application of same in therapeutics |
| 01/27/2005 | US20050020562 Drugs; analgesics; anesthetics; antiarrhythmia agents; antiinflammatory agents ; incontinence; gastrointestinal disorders; neurodegenerative disease |
| 01/27/2005 | US20050020541 Moderate neurotransmitters |
| 01/27/2005 | US20050020540 Biphenylcarboxylic amide derivatives as p38-kinase inhibitors |
| 01/27/2005 | US20050020530 Treatment of parkinson's disease with oligonucleotides |
| 01/27/2005 | US20050020519 Increase concentration of peptide; controlling glucose uptake into cells; adjust metabolism; stimulate cell proliferation; reduce apoptosis; moderate gene expression' |
| 01/27/2005 | US20050020504 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 01/27/2005 | US20050020493 Immunology moderators; plypeptides; prevent inflammation of mucous membrane |
| 01/27/2005 | US20050020492 Melanin-concentrating hormone analogs |
| 01/27/2005 | US20050020481 Ion channel modulating compounds and uses thereof |
| 01/27/2005 | US20050020480 Administering a steroid |
| 01/27/2005 | US20050019908 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 01/27/2005 | US20050019869 Chimeric neuropeptide Y receptors |
| 01/27/2005 | US20050019858 Novel human cytokine/steroid receptor protein |
| 01/27/2005 | US20050019835 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 01/27/2005 | US20050019765 Methods for treating disorders of the nervous and reproductive systems |
| 01/27/2005 | US20050019763 Isolated polypeptide of given sequence; expression vectors, host cells, antibodies, agonists, and antagonists; use in diagnosing, treating, or preventing various disorders |
| 01/27/2005 | US20050019391 Orodispersible tablet having high homogeneity and the preparation method thereof |
| 01/27/2005 | US20050019378 Transdermal drug delivery system of strychnine, brucine, securinine and their salts |
| 01/27/2005 | US20050019343 administering an effective dose of a polypeptide comprising an immunogenic fragment of A beta (SEQ ID NO:1) and an adjuvant in a regime effective to induce an immune response comprising antibodies to the A beta fragment; Alzheimer's disease |
| 01/27/2005 | US20050019330 administering an antibody that specifically binds to the amyloid deposit or a component thereof; can be a human, humanized, chimeric or nonhuman antibody and can be monoclonal or polyclonal; also a novel monoclonal antibody which specifically binds to an epitope within residues 13-28 of A beta |
| 01/27/2005 | US20050019322 Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| 01/27/2005 | US20050019304 Novel human mage-like protein |
| 01/27/2005 | US20050019261 Using serine protease inhibitor; contacting brain tissue; analyzing in variations in protease gene expression |
| 01/27/2005 | CA2800212A1 Histone deacetylase inhibitors and methods of use thereof |
| 01/27/2005 | CA2535034A1 Internallly administered therapeutic agents for diseases in central and peripheral nervous system comprising mesenchymal cells as an active ingredient |
| 01/27/2005 | CA2534095A1 Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments |
| 01/27/2005 | CA2533100A1 Aryl fused azapolycyclic compounds |
| 01/27/2005 | CA2532308A1 Ambroxol for treating epilepsy |
| 01/27/2005 | CA2532216A1 Oligodendrocyte precursor cells and methods of obtaining and culturing the same |
| 01/27/2005 | CA2532093A1 Solid formulation |
| 01/27/2005 | CA2532057A1 Novel azaheterocyclic amides useful for treating pain |
| 01/27/2005 | CA2529790A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative |
| 01/27/2005 | CA2529193A1 Nicotine addiction reducing heteroaryl fused azapolycyclic compounds |
| 01/26/2005 | EP1500707A1 Method of measuring neprilysin activity |
| 01/26/2005 | EP1500654A1 Benzoxazinone derivatives, the preparation and use thereof as medicaments |
| 01/26/2005 | EP1500653A1 Substituted arylpyrazines |
| 01/26/2005 | EP1500402A1 Cell death inhibitor |
| 01/26/2005 | EP1500399A1 Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases |
| 01/26/2005 | EP1500396A1 Reboxetine for treating migraine headaches |
| 01/26/2005 | EP1500395A1 Reboxetine for treating fibromyalgia and other somatoform disorders |
| 01/26/2005 | EP1500391A1 Therapeutic use of bicycloheptane derivatives |
| 01/26/2005 | EP1499735A2 Optimization of transgene expression in mammalian cells |
| 01/26/2005 | EP1499729A1 Derivatives of the nf-kappab inducing enzyme, their preparation and use |
| 01/26/2005 | EP1499724A1 Derivatives of the il-2 receptor gamma chain, their production and use |
| 01/26/2005 | EP1499721A1 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription factors |
| 01/26/2005 | EP1499636A2 Neurotrophic and neuroprotective peptides |
| 01/26/2005 | EP1499631A2 Rna interference mediated inhibition of tgf-beta and tgf-beta receptor gene expression using short interfering nucleic acid (sina) |
| 01/26/2005 | EP1499618A1 Furyl compounds |
| 01/26/2005 | EP1499616A1 Heterocyclic compounds |
| 01/26/2005 | EP1499615A1 Thienyl compounds |
| 01/26/2005 | EP1499613A1 Thioxanthine derivatives as myeloperoxidase inhibitors |
| 01/26/2005 | EP1499611A1 Process for 5- 2(r)- 1(r)- 3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one |
| 01/26/2005 | EP1499610A2 Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them |
| 01/26/2005 | EP1499608A1 Substituted imidazole derivatives: gaba a receptor ligands |
| 01/26/2005 | EP1499606A1 3, 4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists |
| 01/26/2005 | EP1499605A2 NF-KappaB INHIBITORS |
| 01/26/2005 | EP1499601A1 New 2-substituted -1,3-thiazole compounds |
| 01/26/2005 | EP1499600A1 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors |
| 01/26/2005 | EP1499599A1 Substituted pyrazine derivatives |
| 01/26/2005 | EP1499596A1 Muscarinic antagonists |
| 01/26/2005 | EP1499593A1 Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same |
| 01/26/2005 | EP1499591A1 Carboxylic acid amides |
| 01/26/2005 | EP1499589A1 Derivatives of n-phenyl(piperidin-2-yl)methyl benzamide, the preparation method thereof and application of same in therapeutics |
| 01/26/2005 | EP1499588A1 Melanocortin receptor ligands |
| 01/26/2005 | EP1499585A1 Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition |
| 01/26/2005 | EP1499360A2 Formulation comprising buprenorphine |
| 01/26/2005 | EP1499358A1 Ph-sensitive polymer |